Serum angiogenesis‐related VEGF‐A; Th1‐related IFN‐γ and Th2‐related DEFB2 serum expression levels remained significantly higher in patients with moderate‐to‐severe psoriasis after secukinumab treatment than in normal subjects. The gene discussed is VEGFA; the disease is psoriasis.